MYGN
Myriad Genetics IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$457.10M
P/E Ratio
—
EPS
$-3.95
Beta
1.64
52W High
$8.59
52W Low
$3.76
50-Day MA
$4.75
200-Day MA
$6.05
Dividend Yield
—
Profit Margin
-41.30%
Forward P/E
46.08
PEG Ratio
1.40
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Fundamentals
| Revenue (TTM) | $557.00M |
| Gross Profit (TTM) | $379.10M |
| EBITDA | $-111.90M |
| Operating Margin | -21.40% |
| Return on Equity | -23.50% |
| Return on Assets | -7.65% |
| Revenue/Share (TTM) | $7.45 |
| Book Value | $3.94 |
| Price-to-Book | 1.24 |
| Price-to-Sales (TTM) | 0.82 |
| EV/Revenue | 0.626 |
| EV/EBITDA | -23.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -20.80% |
| Shares Outstanding | $94.44M |
| Float | $85.14M |
| % Insiders | 3.33% |
| % Institutions | 103.22% |
Historical Volatility
HV 10-Day
43.02%
HV 20-Day
58.47%
HV 30-Day
56.39%
HV 60-Day
58.72%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($7.42 target)
2
Strong Buy1
Buy7
Hold1
Sell1
Strong SellData last updated: 4/29/2026